DUBLIN--(BUSINESS WIRE)--The "Point of Care & Rapid Diagnostics Market Analysis by Product, by Platform, by Mode of Purchase, End user and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
The point of care & rapid diagnostics market size is estimated to be USD 38.7 billion in 2021 and is expected to witness a CAGR of 12.45% during the forecast period 2022-2029. The increasing frequency of infectious disease, supporting government policies, and the rising number of CLIA-waived POC tests are some of the key drivers for the market growth. Furthermore, healthcare decentralisation and increased investments and funding for product development are expected to contribute the market growth. However, reimbursement reduction and budget restrictions are expected to restrain the market growth.
Segmentation: Point of Care & Rapid Diagnostics Market Report 2021-2029
Product (Revenue, USD Billion)
- Cardiometabolic Monitoring Products
- Glucose Monitoring Products
- Coagulation Monitoring Products
- Infectious Disease Testing Products
- Cholesterol Testing Products
- Faecal Occult Testing Products
- Haematology Testing Products
- Urinalysis Testing Products
- Others
By Platform (Revenue, USD Billion)
- Molecular Diagnostics
- Lateral Flow Assays
- Immunoassays
- Microfluids
- Dipsticks
By Mode of Purchase (Revenue, USD Billion)
- OTC Products
- Prescription-based Products
By End user (Revenue, USD Billion)
- Ambulatory Care Facilities & Physician Offices
- Hospitals
- Clinical Laboratories
- Pharmacies
- Home Care & Self Testing
- Others
By Region (Revenue, USD Billion)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Key Topics Covered:
1. Research Methodology
2. Introduction: Point of Care & Rapid Diagnostics
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Point of Care & Rapid Diagnostics Market
7. Market Analysis by Product
8. Market Analysis by Platform
9. Market Analysis by Mode of Purchase
10. Market Analysis by End user
11. Regional Market Analysis
12. North America Point of Care & Rapid Diagnostics Market
11. Europe Point of Care & Rapid Diagnostics Market
12. Asia PacificPoint of Care & Rapid Diagnostics Market
13. Latin America Point of Care & Rapid Diagnostics Market
14. MEAPoint of Care & Rapid Diagnostics Market
15. Competitor Analysis
16. Company Profiles
17. Conclusion & Recommendations
Companies Mentioned
- Abbott Laboratories (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- bioMerieux SA (France)
- Danaher Corporation (US)
- Quidel Corporation (US)
- QIAGEN N.V. (Netherlands)
- Co-Diagnostics Inc. (US)
- Biocartis NV (Belgium)
- Meridian Bioscience Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Lucira Health Inc. (US)
- Cue Health (US)
- OpGen Inc. (US)
- Binx Health Inc. (US)
- Molbio Diagnostics Pct. Ltd. (India)
- Genomadix (Canada)
- Visby Medical Inc. (US)
- QuikPath PTE Ltd. (Singapore)
- MD-Bio (US)
- QuantuMDx Group Ltd. (UK)
- Aidian Oy (Finland)
- GeneSTAT Molecular Diagnostics LLC (US).
For more information about this report visit https://www.researchandmarkets.com/r/7rynpb
